Teva Pharmaceuticals, recall and blood pressure
Digest more
The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...
Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...
This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaign TD is a chronic movement ...
Teva Pharmaceutical Industries Ltd. will pay $35 million to settle claims it delayed generic competition in the asthma inhaler market.
The main Irish arm of Israeli-headquartered pharmaceutical firm Teva last year paid out dividends of $709.5 million (€617.9 ...
TipRanks on MSN
Teva launches ‘The Other TD’ disease education campaign
Pharmaceuticals announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football ...
Investor's Business Daily on MSN
IBD Rating Upgrades: Teva Pharmaceutical ADR Flashes Improved Price Strength
A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?
Results that may be inaccessible to you are currently showing.
Hide inaccessible results